Quick Answer
MiNK Therapeutics, Inc. reported Operating Income Loss of -$12.64 million for the year ending 2025.
- MiNK Therapeutics, Inc. showed a decrease of -12.0% in Operating Income Loss from 2024 to 2025.
- This data is from MiNK Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$5.92 million | Q1 2021: -$3.01 million | Q2 2021: -$5.61 million | Q3 2021: -$13.38 million | Q1 2022: -$7.37 million | Q2 2022: -$7.70 million | Q3 2022: -$7.99 million | Q1 2023: -$5.85 million | Q2 2023: -$6.34 million | Q3 2023: -$5.22 million | Q1 2024: -$3.83 million | Q2 2024: -$3.07 million | Q3 2024: -$1.88 million | Q1 2025: -$2.70 million | Q2 2025: -$4.05 million | Q3 2025: -$3.18 million.
- Over the full 6 years of available data (2020 to 2025), MiNK Therapeutics, Inc.'s Operating Income Loss has grown by 13.6%.
- Historical annual values: Fiscal year 2025: -$12.64 million | Fiscal year 2024: -$11.29 million | Fiscal year 2023: -$22.92 million | Fiscal year 2022: -$30.95 million | Fiscal year 2021: -$28.36 million | Fiscal year 2020: -$14.64 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: